Search Results

The Barbara Ann Karmanos Cancer Institute has appointed Doris Ranski-Zazula, RN , MSA, as the vice president of the Karmanos Cancer Network, part of McLaren Health Care.

The Barbara Ann Karmanos Cancer Institute has been named one of America’s 2024 Best Hospitals for Cancer Care and one of the country’s 100 Best Hospitals for Patient Experience by the Women’s Choice Award®, America’s trusted referral source for the best in health care.

The Barbara Ann Karmanos Cancer Institute welcomes Wasif Saif, M.D., MBBS, as the new leader of the Phase 1 Clinical Trials Multidisciplinary Team and co-leader of the Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team.

Karmanos Cancer Institute, the largest provider of cancer care and research in Michigan and part of McLaren Health Care, announced that it will be the first provider in the country to offer patients the new FDA-approved TheraBionic P1 device for the treatment of advanced hepatocellular carcinoma, the most common type of liver cancer.

The Barbara Ann Karmanos Cancer Institute welcomes Morhaf Al Achkar, M.D., Ph.D., MSCR, FAAFP, as the associate center director for Education.

The Barbara Ann Karmanos Cancer Institute welcomes Arnold D’Ambrosio as the new Chief Development Officer, effective Monday, July 10, 2023.

PAVmed Inc announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, launched a pilot program and enrolled the first patients on the Veris Cancer Care Platform™ pursuant to a recently-executed memorandum of understanding.

The Barbara Ann Karmanos Cancer Institute, part of Grand Blanc-based McLaren Health Care and a National Cancer Institute -designated Comprehensive Cancer Center, in conjunction with Wayne State University, have named Boris C. Pasche, M.D., Ph.D., FACP, President & Chief Executive Officer and Chair of the Department of Oncology at the Wayne State University School of Medicine.

The Barbara Ann Karmanos Cancer Institute, a leading breast cancer prevention and care provider, has adopted Volpara® Risk Pathways™, a market-leading software program designed to simplify risk assessment and patient management for various cancers, including breast, lung, ovarian, and colorectal cancer.

LIXTE Biotechnology Holdings, Inc., a clinical stage pharmaceutical company, announced a collaboration with Roche and the Netherlands Cancer Institute to conduct a new clinical trial in immune therapy unresponsive metastatic colon cancer.